NORD Hosting ‘RareLaunch’ Workshops to Help Start Rare Disease Non-profits
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops…
Articles by Marisa Wexler, MS
Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
First Case of Ocular MG Following COVID-19 Described in Report
The first published case of a person developing ocular myasthenia gravis (MG) secondary to COVID-19 was described in…
New Phase 3 Trial Data Support Efficacy of Efgartigimod for Generalized MG
Treatment with Argenx‘s investigational therapy efgartigimod leads to significant and early reductions in the severity of generalized…
Changed Levels of Complement-associated Proteins Implicated in Generalized MG, Study Suggests
Altered levels of immune proteins associated with the complement system may be implicated in generalized myasthenia gravis (MG), a…
Patient with Three MG Antibodies Described in Case Report
A patient with three different types of myasthenia gravis (MG)-associated antibodies was described in a recent case report.
IMVT-1401 Seen to Safely Treat Generalized MG in Phase 2a Trial
Treatment with IMVT-1401 significantly eased symptoms and lowered antibody levels in adults with moderate-to-severe generalized myasthenia gravis (MG),…
Levels of suPAR Protein Linked to Myasthenia Gravis Severity
Measuring levels of a protein known as suPAR in the blood could be useful for assessing the severity of…
Argenx Plans FDA Submission of Efgartigimod by Year’s End
Argenx is planning to submit an application to the U.S. Food and Drug Administration (FDA) by the end…
Case Report Describes Late-onset MG in Man Treated for Multiple Myeloma
A 60-year-old man being treated for multiple myeloma was found to have myasthenia gravis (MG) caused by antibodies…